Conference Coverage
about 2 hours ago
Promising Phase 1 Data for Actinium-225 Presented at 2026 ASCO GUabout 3 hours ago
Expanding the Impact of LITESPARK-022 in Renal Cell Carcinomaabout 6 hours ago
Dr Rodriguez: 2026 IASLC TTLC and Next-Gen Targeted Lung Cancer CareTrending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Final KEYNOTE-B96 Analysis Confirms Survival Benefits With Pembrolizumab Regimen in Ovarian Cancer
Navigating Resistance and Intolerance in High-Risk Polycythemia Vera
FDA Issues Tentative Approval to Lu 177 Dotatate Radioequivalent for GEP-NETs
Oncology Frontiers: Recapping a Milestone February for FDA Approvals
CELMoDs: A Distinct Therapeutic Class for Relapsed Multiple Myeloma
Latest News
Shorts










Podcasts

Precision Hope: The New Frontier of AI-Driven Oncology
AI transforms oncology, easing burnout and paperwork, sharpening screening, and helping community clinics handle the coming patient surge.

Community Oncology at a Crossroads: Navigating Policy, Progress, and Practice
Community oncology faces consolidation, policy shocks, AI adoption, and advanced therapies—learn what leaders say to protect local cancer care access.

Navigating the Future of CLL Care
Experts explore the evolving landscape of chronic lymphocytic leukemia treatment, highlighting targeted therapies, MRD strategies, and future innovations.

Supporting Community Oncologists in a GU Research Era
Explore the vital role of community oncology in GU cancer treatment, bridging research and real-world applications for better patient care.

Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
A study reveals the gut microbiome's role in predicting multiple myeloma outcomes, highlighting butyrate-producing bacteria as key indicators of patient survival.

Experts Delve Into Organ Preservation for Genitourinary Cancers
Benjamin Garmezy, MD, and Alexander Kenigsberg, MD, discuss strategies for preserving organs in GU cancers in the Treating Together podcast.

Navigating Modern Lung Cancer Treatment and Clinical Trial Access
Edward S. Kim, MD, MBA, and Neel Shah, MD, discuss advancing lung cancer care and tackling real-world access barriers for community physicians in the Treating Together podcast.

Advancing Prostate Cancer Treatment With Shared Decision-Making
In our first episode of Treating Together, Benjamin Garmezy, MD, and Ralph J. Miller Jr, MD, discuss multidisciplinary prostate cancer care.

Predicting Palbociclib Outcomes in Breast Cancer Using Deep Learning
Xiaojie Zhang, MD, and Akshat Singhal, PhD, discuss their research leveraging deep learning to predict how patients with ER+/HER2- breast cancer will respond to palbociclib.

BMT CTN 1902 in Myeloma: Key Findings With Garfall
In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.
Videos
All News

Logic-gated CAR T A2B543 enters EVEREST-2 arm 2, adding membrane-tethered IL-12 to boost solid-tumor potency while limiting toxicity.

FDA clears real-time AI OCT to spot breast cancer margins during lumpectomy, helping surgeons reduce repeat operations and improve outcomes.

Clinical validation results show changes in methylated circulating tumor DNA (ctDNA) measured prior to treatment initiation and before cycle 3 of therapy were strongly associated with objective response and clinical benefit.

AKY-1189 gains fast track designation in urothelial cancer.

CAPItello-281 shows capivasertib plus abiraterone extends rPFS in PTEN-deficient mHSPC with manageable toxicity and preserved overall quality of life.

IMvigor011 shows post-cystectomy ctDNA timing and levels predict relapse, while adjuvant atezolizumab clears ctDNA and extends survival in MIBC.


FDA grants tentative approval to PNT2003, a Lutathera radioequivalent PRRT for SSTR+ GEP-NETs, paving way for wider access by 2026.

Erica Pimenta, MD, PhD, discussed the goals and key findings from her and her colleagues’ research into IGF-1 and GLP-1 signaling pathways in liposarcoma.

New study links Medicaid expansion to sustained breast cancer survival gains, revealing uneven benefits by race and urging policy action.

Experts explain how MRI trends, seizures, and spectroscopy guide when IDH-mutant glioma monitoring ends and radiation or chemo begins.

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

FDA oncology updates in February 2026 deliver new approvals, oral and monthly dosing options, and key NDA reviews, easing treatment burden across hard-to-treat cancers.

The LITESPARK-024 trial showed a manageable safety profile of belzutifan and palbociclib in advanced RCC but the response rate did not exceed historical single-agent belzutifan.

ASCO GU 2026 previews and FDA rulings spotlight new targeted options in bladder, lung, breast, and colorectal cancers.

Belzutifan/Lenvatinib Bests Cabozantinib in PFS, ORR in ccRCC
Findings from the phase 3 LITESPARK-011 trial favored belzutifan/lenvatinib vs cabozantinib in PFS and ORR.


During a live event, Shaji Kumar, MD, discussed when talquetamab can be sequenced in multiple myeloma as an alternative to targeting BCMA in consecutive lines.

An integrated analysis of the RETAIN-1 and RETAIN-2 trials demonstrates that circulating tumor DNA is a powerful prognostic indicator for metastatic recurrence in muscle-invasive bladder cancer.

Over 50% ORR Achieved With Disitamab Vedotin in HER2+ and HER2-Low Bladder Cancer
Phase 2 results showed efficacy and tolerability of disitamab vedotin in pretreated HER2+ and HER2-low urothelial cancer.

In certain patients with prostate cancer, darolutamide enhanced PSMA expression, according to the Daro-PET study.

Enfortumab Vedotin/Pembrolizumab Redefines Neoadjuvant Therapy for MIBC
Neoadjuvant enfortumab vedotin plus pembrolizumab significantly improved event-free survival and overall survival compared with gemcitabine plus cisplatin.

In an interview, C. Ola Landgren, MD, PhD, delved into the details of the FDA's draft guidance on using MRD as a basis for FDA approvals in multiple myeloma.

Clinical trial data show ovarian cancer survival gaps narrow with diverse enrollment, but disparities persist after progression, spotlighting access, toxicity, and care barriers.

Findings from the phase 1 PAnTHA study demonstrate that actinium-225 was well tolerated with encouraging responses in patients with metastatic castration-resistant prostate cancer.

PEACE-3 data show enzalutamide plus radium-223 extends survival and delays progression in bone-predominant mCRPC, with manageable added toxicity.

During a live event, Joshua Richter, MD, discussed dosing strategies when using selinexor in relapsed/refractory multiple myeloma.

The phase 2 BRCAAway trial demonstrated that abiraterone acetate, prednisone, and olaparib significantly improves progression-free survival and overall survival compared with either agent used alone or sequentially in patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 or ATM alterations.

FDA clears zongertinib for HER2-mutant advanced nonsquamous NSCLC, showing strong responses and promising brain metastasis activity.

Tumor-infiltrating lymphocyte therapy yielded favorable results in a small cohort of patients with soft tissue sarcoma, leading to plans for a larger trial.

Phase 3 interim data show izalontamab brengitecan boosts survival in pretreated metastatic triple‑negative breast cancer, hinting at new standard.

Experts discuss the SWOG S1512 trial of desmoplastic melanoma and the greater relevance of trials of immunotherapy in rare disease states.

Immunotherapy Choices and High Attrition Rates in SCLC
Explore frontline chemo‑immunotherapy choices in extensive-stage SCLC, NCCN updates, and why patient drop-off shapes second- and third-line care.
















































